Chronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South, and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for chronic hepatitis C vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians. However, low efficacy, poor safety profile, and subcutaneous administration limit the use of IFN-based therapies. Superior virologic outcomes have been observed with different classes of direct-acting antivirals (DAAs) alone or in combination, and several alloral DAA regimens are available in Asia. These regimens have shown excellent efficacy and favorable tolerability in clinical trials, yet there is a need for further studies of DAAs in a real world context, particularly in Asia. Furthermore, IFN-free treatment may not be accessible for many patients in the region, and IFN-based regimens remain an option in some countries. There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost-effectiveness of IFN-free regimens. The evolution of potent treatments makes HCV eradication a possibility that should be available to all patients. However, access to these therapies in Asian countries has been slow, primarily because of economic barriers that continue to present a hurdle to optimal treatment.
Introduction
Hepatitis C, a blood-borne infection caused by the hepatitis C virus (HCV), poses a global healthcare burden, especially because of its association with the development of liver cirrhosis, hepatocellular carcinoma (HCC), liver failure, and death. 1 People infected with HCV can progress from a mild illness lasting for a few weeks (acute) to a serious chronic illness. Spontaneous viral clearance within 6 months of infection is observed in approximately 15-45% of patients, while 55-85% of patients develop chronic hepatitis C (CHC). 2 Worldwide, it is estimated that > 184 million people have CHC, with areas of Central, South, and East Asia and North Africa/Middle East reporting the highest prevalence. 2, 3 The prevalence of HCV in the general population of several Asian countries has been estimated to be 1.6% in China, 0.6-1.1% in South Korea, and 1.8-5.5% in Taiwan. 4 In Japan, the estimated prevalence of HCV infection is approximately 1.0-2.0%, suggesting that there may up to 1.5-2 million HCV carriers in the population. 5 The picture is similar in Southeast Asia (Malaysia, Myanmar, Vietnam, Cambodia, Philippines, Thailand), where the HCV prevalence is estimated to be approximately 2.0%. 3 In developing countries, the most common modes of HCV transmission are due to unsafe injection practices, including injections for therapeutic and recreational drug use, inadequate infection control/sterilization procedures, and infected blood or blood products used for blood transfusions. 2, 6 There are seven HCV genotypes (GTs) that have a distinct geographic distribution. 1, 3, 7, 8 Until recently, there was no clear understanding of the role of HCV GTs on the natural history of CHC, but new studies have begun to elucidate their role in HCV disease progression. In East Asian countries including Taiwan and South Korea, GT1b is the most dominant subtype and is associated with a high risk of HCC. 1, [9] [10] [11] [12] [13] GT2 is also prevalent in Japan, South Korea, and Southern Taiwan. 1, 2, 14 GT3 infection is highly prevalent in South and Southeast Asia and is associated with a high risk of steatosis, HCC, and accelerated fibrosis progression. 15, 16 GT4 is not common in East Asia, being more common in Central and North Africa. 1 GT6 is predominant in some areas of South-East Asia, particularly Hong Kong and Vietnam. 1, 8, 14 Challenges and opportunities for hepatitis C virus treatment in Asia. Treatment outcomes for CHC are known to vary by the ethnic origin of the patients. It is well established that Asians have a better sustained virologic response (SVR) following interferon (IFN)-based therapy than non-Asians. [17] [18] [19] [20] This observation is related to physiological and genetic aspects, including the influence of interleukin 28B (IL28B) genes. Single nucleotide polymorphisms (SNPs) appearing near the IL28B gene were evidenced to play an important role in pegylated inteferon (PEG-IFN)-alpha + ribavirin (RBV)-induced HCV RNA clearance in genome-wide association studies. 21, 22 Subsequent meta-analyses suggested that IL28B SNPs significantly affect SVR rates in patients with GT1 and GT4, but the effect is not as pronounced on those with GT2 or GT3 infection. [23] [24] [25] Although the high prevalence of IL28B polymorphisms in Asian populations is associated with more favorable IFN-based treatment responses than observed in Caucasian or African-American patients, 14 several considerations-including low efficacy, numerous adverse events (AEs), broad contraindications, long treatment duration, and subcutaneous administration-limit the use of PEG-IFN. 14, 26, 27 Adding direct-acting antivirals (DAAs) to PEG-IFN can increase the probability of achieving SVR but does not address the AEs and contraindications. [28] [29] [30] [31] Ongoing research now enables superior virologic outcomes with several classes of DAAs alone or in combination, compared with IFN-based therapy (Fig. 1) . Clinical data suggest that DAAs are not only effective against all HCV GTs but can also lead to SVR with shorter duration of treatment (≤ 12-24 weeks). 32, 33 Notably, second-generation DAAs have shown cure rates > 90% within 12 weeks for patients with GT1 disease, compared with SVR rates of~40% with PEG-IFN and RBV after 48 weeks of treatment. 34, 35 Available all-oral DAA regimens in Asia include daclatasvir (DCV) + asunaprevir (ASV), sofosbuvir (SOF) with RBV, SOF/ledipasvir (SOF/LDV), ombitasvir (OBV)/paritaprevir/ritonavir (PTV/r), OBV/PTV/r + dasabuvir (DSV), and DCV + SOF.
These regimens have shown excellent efficacy and favorable tolerability in clinical trials (Table 1) .
Two Phase III studies conducted in Japan with the combination of DCV + ASV demonstrated high SVR rates in patients with GT1b. 43, 44 SVR12 rates of 89.1% and 95.5% were reported in treatment-naive patients and prior PEG-IFN/RBV relapsers, respectively. 44 Lower response rates (SVR24) of 80.5% were observed in non-responders (null and partial) to PEG-IFN/RBV therapy. 43 These results were confirmed in global studies and in analyses of other Asian populations, with SVR12 rates of 90-92.3% achieved in treatment-naive patients, and 78.6-82% in those who failed or who were intolerant/ineligible to prior PEG-IFN/RBV therapy. 45, 46 Importantly, there was no difference in SVR12 rates in patients with or without cirrhosis. 47 Response rates observed with DCV + ASV in clinical trials have been affected by baseline resistance-associated variants (RAVs) primarily in the NS5A region. 47, 48 Two signature NS5A RAVs (L31F/I/M/V and/or Y93H) have been identified as the strongest baseline factors negatively impacting SVR with DCV + ASV, 48 and their prevalence in Asia is highest in Japanese patients (18%) compared with Korean or Taiwanese patients (12.8%). 48 In a pooled analysis of five Asian studies of DCV + ASV in Japan, Korea, and Taiwan, in which patients with baseline RAVs were excluded, SVR rates were shown to be higher: approximately 97% in treatment-naive patients in Korea and Taiwan and up to 100% in treatmentexperienced patients (prior relapsers) in Japan. 48 Compensated cirrhosis did not appear to impact SVR rates when excluding baseline RAVs. 48 Retreatment of patients who did not achieve SVR with DCV + ASV has produced relatively low SVR rates; in one study, 71% of Japanese GT1 patients who received retreatment with SOF/LDV achieved SVR. 49 It is therefore recommended that patients with HCV GT1 receive sub-GT and RAV testing prior to commencing treatment with DCV + ASV. 50 Global clinical studies have also demonstrated high response rates over 12 weeks (> 97%) for SOF/LDV with or without RBV in treatment-naive patients with GT1 infection. 36 A shorter treatment duration of 8 weeks is associated with a higher risk of relapse although SVR rates of approximately 93% have been observed in non-cirrhotic treatment-naive patients. 37, 51 In treatment-experienced patients with cirrhosis, SVR rates with SOF/LDV over 12 weeks were < 90%, which improved with extended treatment duration to 24 weeks. 52 Similarly, high response rates (95-100%) in both treatment-experienced and treatment-naive patients with GT1 disease with or without cirrhosis have been observed with SOF/LDV in Asian studies. 53, 54 However, in patients who failed treatment following 8 or 12 weeks of a SOF/LDV regimen, retreatment with SOF/LDV over 24 weeks produced lower SVR12 rates of 71%. 55 Phase III global studies of OBV/PTV/r + DSV in GT1 disease have included patients with GT1a or GT1b; high SVR rates of 90-100% following 12 weeks of treatment were reported in treatment-naive and treatmentexperienced patients with or without cirrhosis. 39, 40, [56] [57] [58] In cirrhotic patients, SVR rates were higher in patients with GT1b, although response rates improved in patients with GT1a after 24 weeks of treatment. 58 High response rates were also observed in a Phase III study of Japanese patients with GT1 disease who received the all-oral OBV/PTV/r regimen, and SVR rates of 94-97% were reported in both treatment-naive and treatment-experienced patients. 59 In this study, all (100%) treatment-naive cirrhotic patients receiving open-label OBV/PTV/r achieved SVR, whereas SVR rates were lower in treatment-experienced patients with cirrhosis (87.9%). 59 DAAs have also produced high response rates in patients infected with non-GT1 GTs. SOF + RBV for 12 weeks has produced high SVRs in clinical studies of patients with GT2. 33, [60] [61] [62] A Phase IIIb study in Taiwan reported SVR12 rates of 100% in patients with GT2 receiving SOF + RBV for 12 weeks, including those with compensated cirrhosis. 63 The combination of OBV/PTV/r with RBV for 16 weeks produced SVR12 rates of 91.5% and 75.8% in treatment-naive and treatment-experienced Japanese GT2 patients, respectively; however, SVR12 rates over 16 weeks were substantially lower in patients with cirrhosis (33.3%). 64 The regimen of SOF + RBV for 12 weeks has proved efficacious in an Egyptian study of patients with GT4 infection; SVR rates of 78% and 93% after 24 weeks of treatment were reported in patients with or without cirrhosis, respectively. 65 Studies have also demonstrated the high efficacy of SOF in combination with simeprevir (SMV) or DCV, with or without RBV, in patients with GT4 infection over treatment durations of 12 or 24 weeks. 33 Additionally, the combination of OBV/PTV/r with RBV has shown high efficacy in GT4 infections, with SVR rates of 100% reported in non-cirrhotic patients in a recent clinical study. 66 High response rates were also seen in a Phase IIa study of LDV/SOF in treatment- DAA, direct-acting antiviral; HCV, hepatitis C virus; RAV, resistance-associated variants; SVR, sustained virologic response; TE, treatment-experienced; TN, treatment-naive; DCV + ASV, daclatasvir + asunaprevir; SOF/LDV, sofosbuvir/ledipasvir; OBV/PTV/r + DSV, ombitasvir/paritaprevir/ritonavir + dasabuvir; DCV + SOF, daclatasvir + sofosbuvir.
experienced and naive GT4 patients after 12 weeks of treatment. 67 The combination of DCV + SOF has demonstrated high efficacy across HCV GT1, 2, and 3 in a Phase II study of treatment-naive and experienced patients; overall, SVR12 rates were 98%, 92%, and 89% among patients with GT1, GT2, and GT3, respectively. 68 Phase III studies confirmed the pan-genotypic potential of this regimen in challenging patient populations (advanced cirrhosis or post-transplantation, coinfection with HIV), although few patients with GTs other than type 1 were included in the studies. 42, 69 Despite the pan-genotypic success of some DAA regimens, GT3 has proven difficult to cure, with lower response rates observed with DAAs in these patients. 15, 33 However, recent Phase III studies of DCV + SOF AE RBV in patients with GT3 have demonstrated high response rates. 41, 70 The all-oral regimen DCV + SOF produced SVR12 rates of 90% and 86% in treatment-naive and experienced GT3 patients, respectively 70 ; similarly high efficacy was observed with the addition of RBV in patients with advanced liver disease. 41 High efficacy was also reported in a recent Phase III study investigating the combination of SOF + PEG-IFN AE RBV for 12 weeks in treatment-naive and treatment-experienced GT3 patients, which produced overall SVR12 rates of 93%. 28 There are few studies of DAA therapy in patients with GT5 and GT6, although the combination of LDV/SOF for 12 weeks produced SVR rates of 96% in a recent (small) study of patients with GT6 infection. 38 Not only have the newly available DAAs improved efficacy outcomes in patients with CHC, but they are also associated with improved safety and tolerability, resulting in fewer treatment-related AEs than with PEG-IFN-based regimens and first-generation DAAs. 33 However, while DAA therapies offer improved safety, specific AEs are consistently reported in clinical trials, including ALT elevation and nasopharyngitis. 39, 43, 47, 58, 59 Second-generation DAA combinations have exceptional efficacy, but a small proportion of patients may experience virologic failure, especially in a real-world setting. 33 In a large, real-world observational cohort study (N = 4365) of SOF/LDV AE RBV in HCV GT1 infection, SVR rates of 93.2% and 96.6% were reported after 8 and 12 weeks of treatment, respectively, in non-cirrhotic treatment-naive patients with baseline HCV RNA <6 × 10 6 IU/ mL who received SOF/LDV. 51 A recent meta-analysis of clinical trials and real-world observational studies evaluating the effectiveness of SMV + SOF AE RBV in patients with HCV GT1 found that SVR rates reported in observational studies were lower (84%) than those reported in randomized controlled trials (RCTs;94%) with this regimen. 71 The French Observational Cohort ANRS CO22 HEPATHER study is designed to follow up to 15 000 HCV patients over 10 years to collect real-world clinical data. Initial data from the cohort, which includes patients with HCV GT1 who received treatment with SOF + DCV for 12 or 24 weeks (N = 317), showed that SVR12 rates were higher after 24 weeks (93.4%) than 12 weeks of treatment (84.9%). 72 Recent studies with DCV + ASV in Japan have confirmed the high efficacy of this regimen in a real-world Asian setting. An overall SVR12 rate of 94.4% after 24 weeks of treatment with DCV + ASV was recently reported in a real-world study of Japanese patients with HCV GT1 (primarily GT1b); interestingly, 83% (5/6) of patients with baseline RAVs at L31 M or Y93H also achieved SVR12, although the patient numbers were low. 73 These findings extend to challenging patient populations, with SVR rates of 95.5% reported in chronic hemodialysis patients infected with HCV GT1 receiving DCV + ASV in another recent prospective observational study in Japan. 74 Yet, despite these positive findings, there are relatively few real-world studies of DAAs-particularly in Asia-and insufficient data to draw robust comparisons of real-world and clinical trial outcomes in different patient subgroups (e.g., treatment-naive and experienced patients, or cirrhotic and non-cirrhotic patients). 33, 71 Drug-drug interactions (DDIs) have emerged as an additional consideration for HCV treatment in clinical practice, given the number of patients with clinically significant comorbidities and associated concomitant medications. A recent real-world study in Germany evaluated the clinical significance of DDIs between HCV patients' regular outpatient medications and current IFN-free DAA regimens. 75 In this study, the median number of concomitant drugs per patient was two (range, 0-15); regular outpatient medication contained 1-3 drugs in 46% of patients, and 4-6 drugs in 24% of patients. 75 Proton pump inhibitors, such as pantoprazole, were the most frequently used concomitant medications (18.8%). 75 In patients receiving HCV treatment with SOF-based regimens (SOF/RBV, SOF/SMV, SOF/DCV, or SOF/LDV), the incidence of potentially significant DDIs that required monitoring or dose adjustment ranged from 9.6% (SOF/RBV) to 40.2% (SOF/ LDV). 75 For patients receiving HCV treatment with OBV/PTV/ r + DSV, 66.3% experienced clinically significant DDIs; 8.4% of these DDIs occurred where co-administration of outpatient medication was either not recommended or contraindicated. 75 Many DAAs are metabolized via the CYP3A4 enzyme family and are either inhibitors or substrates of P-glycoprotein (P-gp) or OATP1B1/3; DCV, for example, is a moderate inhibitor of both.
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For DCV + ASV therapy, rifampin, dexamethasone, and antifungal agents such as ketoconazole are contraindicated, and statins and digoxins should be used cautiously. Thus, close attention should be given to co-administration of DAAs with inhibitors or inducers of the CYP family, P-gp or OATP1B1/3.
77 Secondgeneration DAAs are generally considered to have lower potential for interactions through P-gp and CYP3A4 than first-generation DAAs. 75 However, some SOF-based regimens have been associated with potentially serious interactions with amiodarone, resulting in severe cardiac-related AEs that warrant ongoing surveillance. 33 Further understanding the impact of DDIs in realworld clinical practice is, therefore, crucial to guide appropriate treatment decisions.
Another unmet need in the treatment of Asian patients with HCV can be the relative paucity of existing data for less common GTs. For example, GT6 is relatively common in patients from Southeast Asia and the surrounding region, with a prevalence of 10-30% in Hong Kong, 14% in Vietnam, and 1.4% in South Korea. 78 However, at present, most of the available data detailing the efficacy of DAAs have been derived from Western countries where GT6 is rarely seen.
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Apart from increased access to better therapies, the success of optimizing HCV management depends on the viability of screening programs and increasing disease awareness. 33 Unfortunately, despite the high rate of HCV infection in Asia, there is a lack of adequate screening programs in the region.
14 A nationwide survey in Taiwan also revealed a large gap between clinical efficacy and community effectiveness in anti-HCV treatment, placing~0.47 million untreated patients at high risk of developing end-stage liver disease. 80 This survey identified fear of AEs, major disorders, ineligibility of insurance reimbursement, and lack of therapy awareness as the primary treatment barriers, with only 36.2% of the included anti-HCV-seropositive subjects identified as having disease awareness. 80 These observations clearly demonstrate that recent advances in HCV treatment are not appropriately utilized in this region. The authors suggested that effective disease awareness programs and recommendations for IFN-free treatment for those with treatment accessibility could improve the overall effectiveness of HCV treatment. 80 A key contributor to the existing burden on healthcare management is the proportion of HCV-infected patients who remain unaware of the condition until they present with advanced symptoms of cirrhosis and HCC. 2 A systematic review by Nguyen et al. suggested that the rate of under-diagnosis of CHC in Asia is very high because of unidentifiable risk factors. 18 In the absence of a vaccine, this unawareness potentially leads to rapid disease transmission.
These multifaceted aspects culminate into an urgent unmet need to optimize CHC management (Fig. 2) . Given the high chances of HCV infection and prevalent endemicity, introduction of preventative measures, such as nationwide screening and surveillance programs, is warranted in Asian countries. The World Health Organization guidelines recommend HCV serology testing for all individuals in a population with high HCV seroprevalence and those with a history of HCV risk exposure. 16 Although this approach is subject to limitations because of geographical differences in identifying risk behaviors, it could be favorable in the long-term prevention of serious complications, as well as in reducing the risk of HCV transmission.
Recently, Kim et al. evaluated the cost-effectiveness of conducting one-time screening for HCV in Korea using a published Markov model on three patient cohorts stratified by age. 81 The investigations concluded that screening was cost-effective in all age groups (40-49, 50-59, and 60-69 years) with treatment costs partially offset by the monetary burden of complications, such as decompensated cirrhosis and HCC. 81 Another study in Japan also concluded that screening for HCV is cost-effective in general and high-risk populations. 82 The obvious economic and epidemiological differences among Asian countries contribute to restrictions in extrapolating the feasibility of such programs on a large scale, and, thus, further data are required. Nevertheless, implementation of targeted screening programs by local governing bodies and healthcare associations, especially in patients aged > 40 years, deserves immediate attention.
Urgency to treat patients with hepatitis C virus in Asian countries. CHC is a slow progressive disease with 15-30% of infected patients developing cirrhosis within 20 years of infection.
2 Of these, 3-6% of cirrhotic patients develop hepatic decompensation, while 1-4% progress to HCC.
83 GT1b, the predominant HCV subtype in Asia, is associated with an increased risk of HCC development. 12, 84 The multivariate risk of HCC development was shown to be 1.85 (95% confidence interval [CI], 1.06-3.22) times higher in Taiwanese patients with GT1b versus non-GT1b. 12 Additionally, a recent population-based cohort study in Taiwan found that CHC infection is temporally associated with a twofold increased risk of lymphoid neoplasms, particularly NonHodgkins lymphoma.
85 A significant association between GT1b infection and progression of liver damage from non-cirrhotic to cirrhotic status has also been demonstrated in Korean patients. 10 Historically, infection because of contaminated blood supply was a key route of infection prior to identification of HCV and screening of blood products. 6 This has resulted in an aging and often unaware patient population that is increasingly at risk of HCC and cirrhosis following decades of chronic infection. Individuals engaging in high-risk activities, such as injecting drug users, are likely to have acquired infection more recently and may therefore have less long-term damage, as duration of infection and age ≥ 40 years at time of infection are risk factors for disease progression. 50 However, such individuals are also at high risk of reinfection, which could increase treatment costs in the long term.
It is known that eradication of HCV has numerous health benefits in patients, including decreased liver inflammation, prevention of liver cirrhosis, and improved extrahepatic outcomes. 86 More importantly, treatment of HCV may reduce disease transmission within the wider community. 16 As presented in Figure 3 , there could be substantial benefits for early versus delayed treatment in clinical practice. A pooled analysis of four randomized controlled trials, including individual data from 3010 treatment-naive patients, indicated an improvement in liver inflammation and necrosis in 39-73% of patients who achieved SVR, with cirrhosis being resolved in 50% of the cases. 87 SVR has also been shown to be associated with a 70-90% decrease in the risk of liver-related outcomes. 88 Recently, Jezequel et al. suggested that initiating therapy in patients with a low stage of fibrosis could have extended benefits for SVR. 89, 90 The group also concluded that 15-year survival rates were significantly higher in patients with SVR, compared with untreated patients and those experiencing treatment failure.
89,90 Additionally, a greater mortality benefit was evident at fibrosis stages < F3 in several model-based studies.
89,91-93 Even in patients with advanced fibrosis secondary to HCV infection, achieving SVR correlated with a decreased need for liver transplantation, HCC, and liver-related mortality, compared with non-SVR patients. 94 Given the strong association between achieving SVR and reduced risk of HCC, wider use of DAA therapy in the future may provide further clinical benefits. 95 Current evidence also supports the use of DAA regimens in HCV patients with decompensated cirrhosis, although long-term studies are required to further evaluate the efficacy and safety of DAAs in this patient population. 96 In CHC patients with GT1b infection, the risk of HCC development is amplified. 9 Multivariate analysis of data from a long-term prospective study suggested that GT1b infection was an independent predictor of HCC development (hazard ratio [HR], 3.02; 95% CI, 1.40-6.53). 9 Additionally, cirrhotic patients with GT1b require constant surveillance for early detection and management of neoplasms. 9 The cumulative lifetime (30-80 years) risk of HCC among Taiwanese patients was significantly higher in those with HCV GT1b (29.7%) than in non-GT1b patients (19.2%; P < 0.001). 12 Because GT1b is dominant in East Asian countries, there is an increased urgency to devise strategies that improve the viability of treatment in this region.
The decision to treat in clinical practice is generally individualized on a case basis and should be considered for all patients with CHC who are willing and can afford this treatment option.
However, the cost of treatment and reimbursement criteria remain the key contributors to guide clinical treatment decisions. The standard treatment cost (US$18 000-33 000) for HCV in Asia Pacific is staggeringly high for patients from low-income countries where medication costs are not covered by the national healthcare programs.
97,98 Nevertheless, these costs can considerably increase with delayed treatment; hence, it is necessary to evaluate the costeffectiveness of early versus delayed treatment. Recently, the modeling the natural history and cost-effectiveness of hepatitis (MONARCH) model was used to determine the cost-effectiveness of initiating standard of care treatment in Japanese patients with HCV GT1b infection. SVR was observed in 90% of the patients treated immediately versus 87.4%, 81.2%, 74.1%, and 66.4% of patients initiating treatment by 1, 3, 5, and 7 years, respectively.
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The results also indicated fewer cases of liver complications, compensated and decompensated cirrhosis and HCC with early treatment.
Although delayed treatment could eventually multiply the cost of treatment when accounting for the severity of liver-related complications, in real-life clinical practice, the financial implications of initiating treatment often outweigh the future considerations. Therefore, in many Asian countries, cost-effectiveness data and the impact of treatment on healthcare budgets play a crucial role in ensuring treatment access. A recent study in Japan assessed the cost-effectiveness and budget impact of treatment strategies involving two DAA regimens, DCV + ASV, and SOF/LDV for patients with HCV GT1b without NS5A RAVs. 100 Costeffectiveness was estimated via the comparison of total costs, quality-adjusted life years, and life years accumulated for each of the treatment regimens. A de novo budget impact model was developed to predict the 3-year cost of two alternative treatment pathways: (1) initiating treatment with DCV + ASV or SOF/LDV, and (2) re-treating failures with the opposite regimen. A minimal difference in benefit was observed between regimens in this model; only an additional 0.022 quality-adjusted life years and 0.002 life years with SOF/LDV. 100 However, there was a significant difference in cost estimates between the two treatment regimens. DCV + ASV was expected to result in a total reduction in cost of ¥4 085 453 (US$40 884). 100 It was predicted that total costs (including treatment and complication management) would more than double with SOF/LDV, from ¥242 to ¥586 billion (US$2.42 to US$5.868 billion), predominantly driven by the acquisition cost of initial treatment (¥228 to ¥580 billion; US$2.28 to US$5.80 billion). 100 The expected cost associated with retreating 603 patients with SOF/LDV was estimated to be ¥8 billion (US$80.0 million). 100 The cost of drugs and healthcare insurance systems differ greatly between countries in Asia; hence, further data on the cost-effectiveness of various DAA therapies in individual countries are urgently needed.
Revisiting the cost of DAA treatment will further bolster the number of patients being treated, consequently helping to control the spread of HCV. To this end, some low-income Asian countries, including India and Indonesia, have arrangements in place with global pharmaceutical manufacturers to allow local licensed generic manufacturing of approved DAAs at lower cost. 14, 50 China has also recently rejected the patent application for SOF, which may potentially lower the cost barrier for treatment, although DAAs have yet to be approved in mainland China. 101 Despite these approaches, challenges to treatment access still remain across Asia in terms of the variability in healthcare systems, infrastructure, and the general affordability of medicine to patients who need treatment.
14 Several international and national treatment guidelines, including the Asian-Pacific Association for the Study of the Liver (APASL) recommendations on the treatment of HCV, now recognize the importance of providing treatment for all patients given the benefits associated with eradicating HCV and no longer recommend prioritizing "high-risk" patients for antiviral treatment. 16, 43, 89, [102] [103] [104] Further focused collaborative efforts from industry, regulatory authorities, and healthcare providers are required to increase the number of patients being treated once DAAs are available at an affordable price in Asia.
Conclusions
Asian countries have a very high prevalence of CHC, with over 50% of HCV patients worldwide living in this region. There is significant scope for improving current clinical practices in HCV management across Asia. Active scaling-up of effective screening programs to determine the burden of HCV and its related complications could be beneficial in this region. Better disease awareness efforts to increase the number of patients receiving treatment and preventing disease transmission are warranted. Recommendations by international guidelines for continuous surveillance on the development of cirrhosis and HCC should be implemented, with the aim of reducing the healthcare burden related to CHC. 16, 43, 89, [102] [103] [104] With the evolution of potent treatments causing rapid viral decay, it is now possible to eradicate this disease completely, and all patients should eventually receive these benefits. Unfortunately, to date, access to new and improved therapeutic options for CHC in Asian countries has been slow. This delay is directly correlated with patient deterioration and increased costs of treatment. Even with accessibility to novel DAAs, economic barriers will likely present a major hurdle to optimal treatment delivery. These concerns require the attention and collaboration of local governments, the pharmaceutical industry, medical societies, and healthcare providers to arrive at the most plausible policies to facilitate viral eradication. 86 While such alternatives are awaited, current practices call for an individualized treatment approach, at the very least for patients that need immediate treatment. This plan should focus on the severity of the disease and the best outcomes that can be achieved with minimal adverse effects and cost of treatment.
